Advertisement


Dejan Juric, MD, on Advanced Breast Cancer: Results From the SOLAR-1 Trial

2018 San Antonio Breast Cancer Symposium

Advertisement

Dejan Juric, MD, of Massachusetts General Hospital, discusses phase III study findings on liquid biopsy–based assessment of PIK3CA mutational status and the combination of the selective PI3K-alpha inhibitor alpelisib plus fulvestrant in the treatment of advanced breast cancer (Abstract GS3-08).



Related Videos

Breast Cancer

Sara A. Hurvitz, MD, on HER2-Positive Breast Cancer: Novel Treatments and Markers

Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses the natural history and novel combinations for HER2-positive disease as well as predictive and prognost...

Breast Cancer

Shanu Modi, MD, on Low HER2-Expressing Breast Cancer: Updated Trial Findings

Shanu Modi, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings from a large phase I study on trastuzumab deruxtecan in patients with low HER2-expressing breast...

Issues in Oncology
Breast Cancer

Reshma Jagsi, MD, DPhil, and Rachel A. Freedman, MD, MPH, on Over- and Undertreatment: Getting It Right

Reshma Jagsi, MD, DPhil, of the University of Michigan, and Rachel A. Freedman, MD, MPH, of Dana-Farber Cancer Institute, discuss the twin challenges of overtreati...

Breast Cancer
Issues in Oncology

Kathy S. Albain, MD, on Breast Cancer, Ethnicity, and Clinical Outcomes: Results From the TAILORx Trial

Kathy S. Albain, MD, of Loyola University Stritch School of Medicine, discusses study findings on race, ethnicity, and patient outcomes in hormone receptor–positive, HER2-negative,...

Breast Cancer

Shom Goel, MD, PhD, on Breast Cancer: Impact of CDK4/6 Inhibitors on Immunity

Shom Goel, MD, PhD, of the Dana-Farber Cancer Institute, discusses preclinical data that suggest CDK4/6 inhibitors not only stop the growth of breast cancer cells, but also enhance...

Advertisement

Advertisement



;
Advertisement